AUTHORS
Ying Wang, MD, PhD, Qingsong Yin, PhD2, Jinhai Ren, MD3, Hongsheng Zhou4, Tiejun Gong5, Feng Zhu6, Xi Zhang, MD7, Wen Qin, MD8, Heng Mei9, Wei Huang10, Zhenghong Chen11, Yuan Hu12, Chenming Xu13, Jianxiang Wang Sr, MD, PhD14
AFFILIATIONS
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
3 The Second Hospital of HeBei Medical University, Shijiazhuang, China
4 Nanfang Hospital, Southern Medical University, Guangzhou, China
5 Institute of Harbin Hematology & Oncology, The First Hospital of Harbin, Harbin, China
6 The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
7 Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, China
8 Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, China
9 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
10 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
11 MSD China, Beijing, China
12 MSD China, Beijing, China
13 MSD China, Beijing, China
14 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Introduction: In the ongoing phase 1b/2 WaveSpan-002 study, MK-1045, a humanized bispecific IgG4 CD19 × CD3 T-cell engager, has shown a manageable safety profile and encouraging antileukemic activity, including high rates of complete response (CR) and minimal residual disease (MRD) negativity in adult participants with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) (Wang et al. Blood. 2025;146[Suppl 1]:647-648; data cutoff: April 25, 2025). We present updated safety and efficacy data from the dose escalation and expansion phase of WaveSpan-002 (NCT05579132).
Methods: Eligible adults with R/R B-ALL, >5% bone marrow blasts, and an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-2 received escalating intravenous doses of MK-1045 administered once weekly. During cycle 1, a step-up dosing strategy was employed, consisting of a priming dose on day 1, an intermediate dose on day 8, and the target dose on day 15, followed by weekly administration of the target dose thereafter, in 28-day treatment cycles. Selected participants received an additional priming dose on day 4 (priming dose 2). Primary phase 1b end points were to evaluate safety, tolerability, and dose-limiting toxicities (DLTs) and to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Secondary phase 1b end points included assessment of efficacy (including rates for CR, CR with incomplete hematologic recovery [CRi], CR with partial hematologic recovery [CRh]) and MRD negativity.
Results: As of the data cutoff date (May 15, 2026), 89 participants were enrolled, of whom 88 had been treated; 83 were treated at 10 dose levels, ranging from 0.15/0.3/0.6 mg (priming/intermediate/target dose) to 2/20/90 mg, and 5 participants were treated at 1/5/20/90 mg (priming/priming dose 2/intermediate/target). The median follow-up time was 26.6 months (range, 0.6-42.4). Median age was 46.0 years (range, 18-73); 43 (49%) were male, 23 (26%) had a Ph-positive diagnosis, 38 (43%) relapsed within 12 months after first remission, and 62 (71%) had an ECOG PS of 1. The median number of prior lines of therapy was 2.0 (range, 1-8); 10 participants (11%) received blinatumomab, 6 (7%) chimeric antigen receptor (CAR) T-cell therapy, and 14 (16%) a hematopoietic stem cell transplant. No DLTs occurred, and the MTD has not been reached. Treatment-emergent adverse events (AEs) of any grade occurred in 88 participants (100%); grade ≥3 treatment-emergent AEs occurred in 81 participants (92%). Death due to an AE occurred in 1 participant (1%; due to hemoptysis), which was determined to be unrelated to MK-1045. Treatment interruption due to an AE occurred in 36 participants (41%). Dose reduction due to an AE occurred in 1 participant (1%), and no treatment discontinuations occurred due to an AE. The most frequent AEs were white blood cell decreased (81%; grade ≥3: 65%), neutrophil count decreased (75%; grade ≥3: 63%), platelet count decreased (68%; grade ≥3: 43%), and lymphocyte count decreased (65%; grade ≥3: 65%). Cytokine release syndrome occurred in 42 participants (48%), with 4 participants (5%) experiencing grade 3 events; no grade 4 or 5 events occurred. Neurotoxicity AEs occurred in 15 participants (17%); all were grade 1 and 2, and the most frequent AE was headache (7%). No immune effector cell–associated neurotoxicity syndrome was observed. Among 87 participants with sufficient follow-up to reach an efficacy evaluation, 50 participants (57%) achieved CR/CRi/CRh. Median time to CR/CRi/CRh was 27.5 days. For 31 participants who received target doses of ≥60 mg, 25 participants (81%) achieved CR/CRi/CRh, and the median duration of CR/CRi/CRh was not reached. A total of 22 of 25 participants who received target doses of ≥60 mg with a CR/CRi/CRh achieved MRD negativity. Among participants with prior exposure to blinatumomab or CAR T-cell therapy who had received a target dose ≥60 mg, 9 of 9 participants achieved CR/CRi/CRh and 8 achieved MRD negativity. Evaluation of RP2D is ongoing.
Conclusion: With extended follow-up, MK-1045 continued to show a manageable safety profile in adults with R/R B-ALL, with no new safety concerns. Durable responses were maintained, supporting the encouraging antileukemic activity of MK-1045 and its ongoing evaluation in B-ALL.
DISCLOSURES
Ying Wang, MD, PhD: No relevant conflicts of interest to declare.